🩸 Prick. Dry. Detect: A Scalable Blood Test for Alzheimer's Pathology

🧠🩸 A finger-prick may change how we detect Alzheimer's disease. A new Nature Medicine study shows that dried capillary blood spots can reliably measure key Alzheimer's biomarkers—p-tau217, GFAP, and neurofilament light—with strong concordance to venous plasma and cerebrospinal fluid results. 📊 In the DROP-AD multicenter study (7 sites, 337 participants), capillary p-tau217 correlated strongly with plasma (r≈0.74) and predicted amyloid pathology with good accuracy (AUC ≈0.86).   🚀 Why this matters: • Enables minimally invasive, scalable, and potentially remote testing • Expands access for population screening, prevention trials, and underserved groups (including Down syndrome) • Moves us closer to earlier, equitable detection—though not yet ready for routine clinical decision-making   Small drop. Big signal. The future of Alzheimer's research may be at our fingertips. ✨